Menu Search
Equities

Sangamo Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0R1D:LSE

Sangamo Therapeutics Inc

Actions
  • Price (USD)0.3715
  • Today's Change-0.021 / -5.23%
  • Shares traded105.35k
  • 1 Year change-67.12%
  • Beta1.3351
Data delayed at least 20 minutes, as of Feb 11 2026 15:28 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

  • Revenue in USD (TTM)32.88m
  • Net income in USD-108.91m
  • Incorporated1995
  • Employees183.00
  • Location
    Sangamo Therapeutics Inc501 Canal Blvd.RICHMOND 94084United StatesUSA
  • Phone+1 (510) 970-6000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.sangamo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.